Platelet-activating factor and oxidized LDL induce immune activation by a common mechanism

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 5, 1997, Pages 963-968

  Frostegård, Johan ^a   Huang, Yi Hui ^a   Rönnelid, Johan ^a   Schäfer Elinder, Liselotte ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

atherosclerosis; interferon gamma; oxidized LDL; platelet activating factor; tumor necrosis factor

Indexed keywords

BEPAFANT; GAMMA INTERFERON; LOW DENSITY LIPOPROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; HUMAN; HUMAN CELL; IMMUNE SYSTEM; INFLAMMATION; LEUKOCYTE; LIPID PEROXIDATION; PRIORITY JOURNAL; THROMBOGENESIS; THROMBOSIS;

EID: 0006401474     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.5.963     Document Type: Article

References (15)

1. Morley J, Sanjar S, Page CP, Bretz U. The role of circulating cells in skin reactions. Br J Dermatol. 1985;113:86-90.
2. Warren JS, Mandel DM, Johnson KJ, Ward PA. Evidence for the role of platelet-activating factor in immune complex vasculitis in the rat. J Clin Invest. 1989;83:669-678.
3. Evangelou AM. Platelet-activating factor (PAF): Implications for coronary heart and vascular diseases. Prostaglandins Leukot Essent Fatty Acids. 1994;50:1-28.
4. Vivier E, Deryckx S, Wang JL, Valentin H, Peronne C, de Vries JE, Bernard A, Benveniste J, Thomas Y. Immunoregulatory functions of paf-acether, VI: Inhibition of T cell activation via CD3 and potentiation of T cell activation via CD2. Int Immunol. 1990;2:545-553.
5. Behrens TW, Goodwin JS. Control of human T cell proliferation by platelet-activating factor. Int J Immunopharmacol. 1990;12:175-184.
6. Bourgain RH, Maes C, Braquet P, Andries R, Torqui L, Braquet M. The effect of 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine (PAF-acether) on the arterial wall. Prostaglandins. 1985;30:185-197.
7. Feliste R, Perret B, Braquet P, Chap H. Protective effect of BN 52021, a specific antagonist of platelet-activating factor (PAF-acether), against diet-induced cholesteryl ester deposition in rabbit aorta. Atherosclerosis. 1989;78:151-158.
8. Stafforini DM, McIntyre TM, Carter ME, Prescott SM. Human plasma platelet-activating factor acetylhydrolase: association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem. 1987;262:4215-4222.
9. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
10. Libby P, Hansson GK. Biology of disease: involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest. 1991;64:5-15.
11. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
12. Hessler JR, Morel DW, Lewis J, Chisholm GM. Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis. 1983;3:215-222.
13. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Bamshad B, Esterson M, Fogelman AM. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest. 1990;85:1260-1266.
14. Frostegård J, Haegerstrand A, Gidlund M, Nilsson J. Biologically modified low density lipoprotein increases the adhesive properties of vascular endothelial cells. Atherosclerosis. 1991;90:119-126.
15. Frostegård J, Nilsson J, Haegerstrand A, Hamsten A, Wigzell H, Gidlund M. Oxidized low-density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc Natl Acad Sci U S A. 1990;87:904-908.